SH-M86

SH-M86 is an orally bioavailable, small-molecule inhibitor specifically targeting the KRAS G12C mutation, developed by Nanjing Sanhome Pharmaceutical. KRAS is a member of the RAS family of GTPases that act as molecular switches in cell signaling pathways; the G12C mutation keeps the protein in a constitutively active state, driving oncogenesis. SH-M86 covalently binds to the cysteine residue at position 12 of the mutant KRAS protein, trapping it in its inactive GDP-bound conformation and thereby inhibiting downstream signaling and tumor cell proliferation. It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer, harboring the KRAS G12C mutation.